UroToday

WSAUA 2025: Long-Term Outcomes of Primary Chemoablation of New-Onset or Recurrent Low Grade Upper Tract Urothelial Carcinoma with UGN-101, a Mitomycin …

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...
UroToday

WSAUA 2025: Impact of Neoadjuvant Systemic Therapy on Tumor and Tumor Thrombus Regression in Renal Cell Carcinoma with Venous Involvement: A Retrospective Analysis

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...
UroToday

Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...
UroToday

WSAUA 2025: Comparative Performance of UNFOLD AI, PSMA-PET, and mpMRI for Prostate Cancer Localization and Pathologic Staging

Dr. Lee concluded his presentation discussing the comparative performance of UNFOLD AI, PSMA-PET, and mpMRI for prostate ...
UroToday

WSAUA 2025: Impact of Bone Protecting Agents on Outcomes with Enzalutamide, with or without Radium-223, in Asymptomatic/mildly Symptomatic Patients with Bone mCRPC from PEACE-3

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...
UroToday

WSAUA 2025: First Results from BOND-003 Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High Risk, Papillary Only ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...
UroToday

WSAUA 2025: Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk NMIBC

For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...
UroToday

WSAUA 2025: PIVOT-006: Ongoing Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk NMIBC

Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...
UroToday

Pasritamig Bispecific Antibody in Metastatic Castration-Resistant Prostate Cancer - Mark Stein

Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...
UroToday

Complications & Adverse Events – External Urinary Catheters

An external urine collection device (EUCD) may be external and less invasive but they are not free of risks. Complications and adverse effects include skin lesion/ulceration and breakdown from ...
UroToday

Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration-Resistant Prostate Cancer Patients Metastatic to Bone (EORTC-1333-GUCG ...

Radium-223 + Enzalutamide in mCRPC: Revisiting PEACE-3 Trial Data - Kristine Peregrino Lacuna PEACE-3 Trial: Enzalutamide Plus Radium-223 Improves Survival in mCRPC, Journal Club - Rashid Sayyid & ...
UroToday

Comparison of Open vs Laparoscopic Nephrectomy: Outcomes and Complications

INTRODUCTION: Nephrectomy is indicated in patients with an irreversibly damaged kidney. The nephrectomy can be performed through open or laparoscopic procedure. Although there is evidence that ...